CSF1R and neoplasm: In vitro, in vivo, and clinical blockade of macrophage CSF-1R with a monoclonal antibody (RG7155) strongly reduced TAM migration and infiltration into the tumor site and the CD8+/CD4+ T cell ratio (Ries et al., 2014).